| Metric | Value (₹ Cr) | vs Q1 FY27 |
|---|---|---|
| Revenue | 40.28 | 34.7% |
| Total Income | 40.81 | 35.6% |
| Expenditure | 39.48 | 33.7% |
| PBT | 1.32 | 136.6% |
| Net Profit | 1.37 | 156.9% |
| OPM | 13.01% | 0.25pp |
| NPM | 3.35% | 1.58pp |
| EPS | 0.25 | 212.5% |
Beds Multiply, Occupancy Stalls—And Margins Get Thinner
Reported profit soared 541%, but it's off a vanishingly small base. The real story: occupancy fell to 38% from 48% despite bed expansion, leaving the ₹1.4 Cr PAT vulnerable to any cost bump. Management's confidence in long-term upside rests on a single bet: will new hospitals ramp.
₹40.3 Cr
✓ Claim ₹40 Cr delivered
₹1.4 Cr
+541.6% YoY (off ₹0.2 Cr base)
3.4%
Paper-thin; zero cost cushion
38%
−10pp YoY; new units 27%
On paper, PAT jumped over 5× year-on-year. In substance, Arvaya delivered its first full consolidated quarter with occupancy compressed from 48% to 38%—the defining tension of the results. The company added 255 beds in six months, but new hospitals are running at 27% occupancy while mature units hold 46–56%. That spread is the occupancy ramp risk that management must solve, and it's what the market is pricing.
Claims vs. what holds up
Q2 revenue ₹40 Cr
Delivered ₹40.3 Cr
Supported
PAT ₹1.37 Cr
Delivered ₹1.4 Cr
Supported (minor rounding)
EBITDA margin 13% sustainable
Q2 OPM 13.0%; H1 13.1%
Supported
Occupancy fell to 38% from 48% YoY
517-bed base (up 255 YoY); new units 27%, mature 46–56%
Supported (explained but concerning)
ARPOB rose 17% YoY
Transcript: specialty mix shift to cardio, neuro, kidney, robotic surgery
Supported
Every core claim checks out. But the footnote matters: revenue growth masked occupancy dilution. Mature hospitals are firing (Hubballi at 56.5%, others 46–56%), but new acquisitions dragging at 27% are pulling the blended rate down. That's not fraud—it's transparency. The real question is velocity: how fast do new units ramp to 40–50%?
What changed on this call
Suhodha GI (Sigipl) acquired Nov 1 at ₹1 Cr/month revenue run-rate
Tech spend earmarked: ₹4.5 Cr capex (rights issue), ₹2–3 Cr annual cost going forward
MyArvaya app timeline set: go-live next quarter with patient engagement features
Occupancy compression now explicit (prior Q: implicit); 27% new units vs 48% mature units highlighted
No formal FY27 or FY28 revenue guidance; bed roadmap only (791 by Dec, 2,400 by FY30)
How the street is positioned
The stock has priced in disappointment. At ₹101.65, Arvaya is trading 29.9% below its all-time high of ₹145, and sitting below both its 20-day (₹109.23) and 50-day (₹114.09) moving averages. RSI at 37.2 indicates oversold territory—not capitulation, but sellers have had the floor. Volume is normal; there's been no panic dumping.
Ownership tells a quieter story. Promoter stake has trimmed to 28.33% from 30.62% a quarter ago—a 229 basis point slide. FII and DII ownership remain at 0%. On a stock down 30% from ATH, the promoter stepping back (even slightly) signals no conviction at higher prices. This is not a bull's market; it's a wait-and-see market.
The bull-bear ledger
Bed expansion roadmap is quantified and on track (517 → 791 by Dec, 2,400 by FY30)
EBITDA margin protected at 13–14% despite occupancy ramp headwind
ARPOB up 17% YoY; specialty mix shift (cardio, neuro, kidney, robotic) is real and sticky
Asset-light lease model reduces capex friction and balance-sheet strain
Government business (15–20% of revenue) provides stable occupancy base
Occupancy fell to 38% from 48% YoY despite bed additions—a 10pp hit
New units stuck at 27% occupancy; path to 40–50% ramp is assumed, not proven
NPM 3.4% is hair-thin; zero room for wage or energy cost inflation
Tech spend (₹4.5 Cr capex + ₹2–3 Cr annual) has no proven monetization timeline; MyArvaya engagement-first, revenue later
Diagnostic network plans vague; analysts' probes on lab/imaging rollout got deflected ('in pipeline, can't disclose')
Risks ranked by what should concern a holder
Occupancy ramp-up stalls
HIGHNew units at 27% need to reach 40–50% by FY28 for margin upside. If they plateau at 30–35%, PAT margins compress further, and the HMO thesis loses its scale lever.
PAT margin erosion on cost inflation
MEDIUMNPM 3.4% leaves zero cushion. Hospital wage and energy costs are rising. Any inflation not offset by ARPOB growth hits earnings hard.
Tech monetization misses
MEDIUM₹4.5 Cr capex + ₹2–3 Cr annual cost on MyArvaya is committed spend. If engagement doesn't translate to revenue by FY28, it becomes a drag, not a growth engine.
MoU pipeline execution slips
MEDIUM220 beds signed (Jalna, Sangli, Shivamogga). If fit-out or operationalization delays push into FY28, the 2,400-bed FY30 target becomes a stretch.
Geographic concentration
LOWHubballi (56.5% occupancy) is the flag-bearer. Interstate expansion is unproven. Single-state dependency on Karnataka/Maharashtra limits optionality.
The debate
What to watch next
1 · December 2026 bed milestone
Does Arvaya hit the 791-bed target by year-end? This is the first quantified waypoint. Hit = confidence in execution; miss = red flag on integration velocity.
2 · Q3 FY27 results: occupancy and MyArvaya launch
New units' occupancy trend is the lynchpin. Any improvement toward 35%+ justifies the ramp thesis. MyArvaya's patient-engagement metrics matter: are 30,000+ SeCURE records in app, and is adoption tracking for external revenue?
3 · FY28 EBITDA margin hold
If occupancy drifts to 35–37% and EBITDA margin stays 13–14%, the HMO model works at scale. If margin slips to 12% or below, cost inflation or unit economics are worse than management guided.
Arvaya is not a turnaround or a turbo—it's a consolidation franchise in its first full year as a combined entity. The quarter proves the bed strategy works (517 operational, +255 YoY) and EBITDA margins hold. What it also proves is that occupancy ramp is slower than a mature operator (38% vs 48% despite scale). The street's 30% drawdown from ATH reflects that trade-off: long-term upside is real, but near-term uncertainty is priced at a risk premium.
For a holder, the single number to track is occupancy in Q3. If new units cross 35%, the ramp thesis survives. If they stay near 27–30%, PAT margins stay under pressure, and the turnaround calendar extends. EBITDA margins will likely hold at 13–14%, but net profit—the number that matters—depends entirely on whether the Jalna, Sangli, and Shivamogga units operationalize on time and ramp faster than the first cohort.
Expansion on track, occupancy ramp a near-term headwind
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
First full consolidated year; acquisition dilution explained transparently, occupancy compression expected but needs 50%+ ramp.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong bed expansion roadmap (2,400 by FY30) and stable EBITDA margins (13-14%) underpin long-term upside, but Q2 occupancy fell to 38% from 48% YoY despite bed additions, signaling near-term ramp-up risk. PAT margins thin at 3.4%, vulnerable to cost inflation.
₹40.3 Cr
Revenue · +null% YoY₹1.4 Cr
Reported PAT · +541.6% YoYFlat
Margins · vs guidance: CorroboratedDid the claims hold up?
Q2 revenue INR40 crores
METDelivered Q2 revenue ₹40.3 Cr
PAT INR1.37 crores in Q2
METDelivered PAT ₹1.4 Cr (minor rounding difference)
EBITDA margin 13% in Q2
METDelivered OPM 13.0%, consistent with stated 13% EBITDA margin
Occupancy declined to 38% from 48% YoY
METOccupancy compression documented; new units at 27%, mature at 46-56%
ARPOB rose 17% YoY
METTranscript states average revenue per bed improved 17% YoY; revenue growth 35% QoQ with 262→517 bed base suggests revenue/bed growth
Earnings quality
What changed since the last call
Occupancy guidance implicit
DowngradeNo prior formal guidance; Q2 showed 38% occupancy vs 48% a year ago due to new unit drag
Suhodha acquisition closed Nov 1
New₹1 Cr monthly revenue run-rate, ₹70-80 lakh profit; pure bolt-on to SeCURE GI network
Tech spend earmarked
New₹4.5 Cr for rights issue tech (SecurANT, GIT), ₹2-3 Cr annual cost going forward; MyArvaya monetization deferred
The Q&A
Q&A was probing and candid. Analysts pressed on occupancy decline, margin sustainability, and government scheme exposure; management deflected none, explained each squarely (new units mature slower, government schemes ~15-20% of business, EBITDA 13-14% sustainable). One soft answer: diagnostic network plans left vague ('in pipeline, can't disclose'). Overall: direct, no evasion.
Occupancy ramp — Vikrant Sahu, RK Advisors
AnsweredNew acquisitions (262→517 beds) have 27% occupancy; mature units 46-56%. Discharges up >20% YoY, occupancy growing QoQ. Ramp as units fit-out and new MoUs operationalize.
ARPOB drivers — Vikrant Sahu, RK Advisors
AnsweredSpecialty mix shift to super-specialty (cardio, neuro, kidney, robotic surgery) and surgery work; pricing minimal in inflation. All hospitals super-specialty majority.
Government scheme exposure — Vikrant Sahu, RK Advisors
AnsweredGovernment business ~15-20%, oscillates 15-20%. Profitability higher at payer/private; government business helps occupancy utilization and overall EBITDA.
Borrowing & capex — Jimit Mehta, Mehta Investments
AnsweredBorrowings for capex and medical equipment fit-outs as beds ramp. Operating cash flow up 89% of EBITDA in H1; no liquidity stress. Rights issue (₹206 Cr) funds new medical equipment and acquisitions.
New hospital margins — Jimit Mehta, Mehta Investments
PartialRegular hospitals mature; new increasing in occupancy. EBITDA margins sustainable 13-14% long-term. Some time till acquisition hits 50%+ occupancy, then EBITDA margin improves.
Sigipl acquisition update — Jimit Mehta, Mehta Investments
AnsweredSpecialized GI hospital (pancreatic, liver surgeries), ₹1 Cr monthly turnover, 100% share swap, no cash outlay. Grows gastrointestinal specialty and builds on SeCURE GI network.
Cybersecurity & data privacy — Shravan Modi, Syndicate Family Office
AnsweredArchitecture ground-up HIPAA/HL7/FHIR/DPDP compliant. Clinical intelligence engine agnostic to HIS, sits outside; consent built-in. All tech stack compliant; consent wired into everything.
Goa resort repurposing — Shravan Modi, Syndicate Family Office
PartialBeing repurposed for wellness. Currently low occupancy (repurposing in progress); numbers will be available next quarter.
Diagnostic network expansion — Viraj Shah, Vairag Capital
DodgedDiagnostics very key; building lab and home collection services. Feeders (sub-labs nearby) planned; integrated lab model going forward. Details 'in pipeline,' can't discuss yet.
MyArvaya monetization — Jignesh, North Star Investments
Partial35,000+ OPD patients/month; app live in SeCURE network. Monetization not yet; engagement first. By next quarter, all SeCURE patients in app. Longer-term external digital health/continuity use.
Tech spend & ROI — Jignesh, North Star Investments
Answered₹4.5 Cr capitalized on rights issue (SecurANT, GIT license). Annual cost ₹2-3 Cr max as usage/volume scale. High capex now, but normalized as growth happens.
Guidance
No explicit FY27/FY28 revenue target stated
MediumBed expansion roadmap (791 by Dec, 2,400 by FY30) is qualitative; no revenue CAGR or FY27 absolute number given
EBITDA margin 13-14% sustainable going forward
HighQ2 at 13%, H1 at 13.1%. Management expects range 13-14% even as acquisitions ramp to 50%+ occupancy
₹2-3 Cr annual tech spend; ₹23.6 Cr per 100-bed hospital
MediumRights issue ₹206 Cr earmarked for tech, medical equipment, acquisitions. Lease model dominant (asset-light)
Risks the call surfaced
Occupancy ramp-up
HighNew units (262→517 beds in 6m) running at 27% vs mature units 46-56%; occupancy compression to 38% vs 48% YoY
PAT margin erosion
MediumPAT margin 3.4% is very thin; hospital wage/energy costs rising; leverage at 0.45x equity means less buffer
Tech monetization uncertainty
MediumMyArvaya app spend ₹4.5 Cr capitalized; ₹2-3 Cr annual cost going forward; monetization deferred to 'later' (beyond engagement phase)
Geographic concentration
LowHubballi unit at 56.5% occupancy; Karnataka/Maharashtra dominate. Interstate expansion (Jalna, Sangli, Shivamogga) pending execution
Acquisition integration
Low255 beds added in 6m; Sigipl (Suhodha GI) added Nov 1 at ₹1 Cr monthly revenue; fit-out and ramp-up timelines uncertain
Management
Score 7/10. Clear on strategy (HMO, tech, bed roadmap). Transparent on occupancy headwinds (new units at 27%). Deferred diagnostic expansion details ('in pipeline, can't discuss yet') but no evasion on core metrics. First full consolidated year; H1 on track (₹70.19 Cr revenue, 13.1% EBITDA margin). Acquisitions diluting occupancy (38% vs 48%) but as expected. ARPOB +17% shows quality upside offsetting volume dilution.
1 · Dec 2026
791 beds target; Sushodha GI ramp
2 · Q3 FY27
MyArvaya app launch with patient engagement features
3 · FY27 end
MoU 220 beds (Jalna, Sangli, Shivamogga) execution begins
PAT margins thin at 3.4%, vulnerable to cost inflation.